Science News
from research organizations

Aspirin protects against Barrett's esophagus, study suggests

Date:
July 23, 2012
Source:
American Gastroenterological Association
Summary:
Aspirin use appears to reduce the risk of Barrett's esophagus, the largest known risk factor for esophageal cancer.
Share:
       
FULL STORY

Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

"The protective effect of aspirin use appears robust because the analyses suggests a dose-response relationship in which high-dose aspirin was significantly associated with decreased Barrett's esophagus risk," said Chin Hur, MD, MPH, of the Massachusetts General Hospital Institute for Technology Assessment and lead author of this study. "It would not be advisable at this time for patients to start taking aspirin, particularly at higher doses, if preventing Barrett's esophagus is the only goal. However, if additional data confirms our findings and an individual at high risk for development of Barrett's esophagus and esophageal cancer also could derive additional benefits, most notably cardiovascular, aspirin could be a consideration."

Dr. Hur and his team of researchers analyzed characteristics of 434 BE patients for factors that might be used in screening and management. In addition to finding that those taking aspirin were 44 percent less likely to have BE, they also found that men were more than three times more likely to develop BE than women.

The incidence of esophageal cancer has been increasing at an alarming rate during the past few decades; current attempts at targeted screening for this type of cancer focus on identifying BE. Nonsteroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, have been associated with reduced esophageal cancer incidence. Although there have been many studies analyzing NSAID and aspirin chemoprevention for esophageal cancer or BE progression to this cancer, few have explored NSAIDs for BE prevention.


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zehra B. Omer, Ashwin N. Ananthakrishnan, Kevin J. Nattinger, Elisabeth B. Cole, Jesse J. Lin, Chung Yin Kong, Chin Hur. Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. Clinical Gastroenterology and Hepatology, 2012; 10 (7): 722 DOI: 10.1016/j.cgh.2012.02.031

Cite This Page:

American Gastroenterological Association. "Aspirin protects against Barrett's esophagus, study suggests." ScienceDaily. ScienceDaily, 23 July 2012. <www.sciencedaily.com/releases/2012/07/120723134638.htm>.
American Gastroenterological Association. (2012, July 23). Aspirin protects against Barrett's esophagus, study suggests. ScienceDaily. Retrieved May 26, 2015 from www.sciencedaily.com/releases/2012/07/120723134638.htm
American Gastroenterological Association. "Aspirin protects against Barrett's esophagus, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/07/120723134638.htm (accessed May 26, 2015).

Share This Page: